Adderall pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers for "Adderall pharmacokinetics"
Adderall Pharmacokinetics: Absorption, Distribution, and Metabolism
Adderall, a mixed amphetamine salt, is available in both immediate-release (IR) and extended-release (XR) formulations. The pharmacokinetics of Adderall show significant variability between individuals, with coefficients of variation ranging from 28% to 56% for key parameters such as maximum concentration (Cmax) and time to maximum concentration (Tmax) . The drug contains both dextroamphetamine and levoamphetamine isomers, typically in a 3:1 ratio, and their plasma concentrations are highly correlated .
Immediate-Release vs. Extended-Release Formulations
The immediate-release form of Adderall is rapidly absorbed, with peak effects and plasma concentrations typically observed within 1.5 hours after administration. The duration of action is dose-dependent, with higher doses resulting in a longer time to peak effect and extended duration of action, but effects generally dissipate by the end of the day .
In contrast, the extended-release formulation (Adderall XR or SLI381) is designed for once-daily dosing. It produces a delayed Tmax, with average increases of about 3 hours for both dextroamphetamine and levoamphetamine compared to the IR formulation . This extended Tmax allows for a longer duration of therapeutic effect, with significant activity maintained up to 10.5–12 hours post-dose, especially at higher doses 14.
Dosing Strategies and Plasma Concentration Profiles
Comparisons between once-daily and twice-daily dosing of Adderall IR show that while morning plasma concentrations of amphetamine are similar, afternoon concentrations are about twice as high with twice-daily dosing. This results in better maintenance of behavioral and cognitive improvements into the afternoon with the twice-daily regimen . The extended-release formulation, however, provides a similar sustained effect with a single morning dose, reducing the need for in-school dosing and potentially lowering the risk of dose diversion .
Bioequivalence of Extended-Release Amphetamine Products
Studies in healthy adults have shown that new extended-release amphetamine oral suspensions are bioequivalent to Adderall XR, with similar Cmax and area under the curve (AUC) values for both d- and l-amphetamine isomers. This means that these products can be expected to have similar pharmacokinetic profiles and clinical effects .
Cardiovascular Effects and Safety Considerations
Acute administration of Adderall leads to significant increases in blood pressure, heart rate, and plasma norepinephrine levels, even in healthy adults at rest. These effects are observed within 3 hours of dosing and highlight the need for careful monitoring of cardiovascular parameters, especially in individuals with pre-existing risk factors .
Conclusion
Adderall’s pharmacokinetics are characterized by rapid absorption and dose-dependent duration of action for the immediate-release form, while the extended-release formulation provides a delayed and prolonged effect suitable for once-daily dosing. Both formulations show substantial inter-individual variability, emphasizing the importance of individualized dose titration. Extended-release products are bioequivalent and offer practical advantages in dosing convenience and sustained symptom control. However, the potential for acute cardiovascular effects underscores the need for careful patient selection and monitoring during treatment 1234+2 MORE.
Sources and full results
Most relevant research papers on this topic